Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

5141 - Mutational profiling of tumor tissue and sequential plasma illustrates emergent clones during treatment in late stage small cell lung cancer (SCLC)

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Tumour Site

Small Cell Lung Cancer

Presenters

Stephanie Yaung

Citation

Annals of Oncology (2019) 30 (suppl_5): v710-v717. 10.1093/annonc/mdz264

Authors

S. Yaung1, C. Woestmann2, L. Xi1, C. Ju3, B. Hinzmann4, M. Thomas5, F. Lasitschka6, M. Meister7, M. Schneider5, F.J.F. Herth8, T. Muley7, B. Wehnl9, J. Palma10, X.M. Ma10

Author affiliations

  • 1 Bioinformatics, Roche Sequencing Solutions, Inc., 94588 - Pleasanton/US
  • 2 Bioinformatics, Roche Sequencing Solutions, Inc., D-14473 - Potsdam/DE
  • 3 Biometrics, Roche Molecular Systems, Inc., 94588 - Pleasanton/US
  • 4 Ngs Lab, Roche Sequencing Solutions, Inc., D-14473 - Potsdam/DE
  • 5 Medical Oncology, Thoraxklinik Heidelberg, 69126 - Heidelberg/DE
  • 6 Pathology, Thoraxklinik at Heidelberg University Hospital, 69126 - Heidelberg/DE
  • 7 Oncology, Thoraxklinik Heidelberg, 69126 - Heidelberg/DE
  • 8 Pneumology, Thoraxklinik Heidelberg, 69126 - Heidelberg/DE
  • 9 Medical Scientific Affairs, Roche Diagnostics GmbH, 82377 - Penzberg/DE
  • 10 Medical & Scientific Affairs, Roche Sequencing Solutions, Inc., 94588 - Pleasanton/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5141

Background

SCLC is an aggressive disease with poor prognosis. Despite initial response to chemotherapy and radiotherapy, relapse occurs in most cases. To characterize genomic changes in SCLC over the course of therapy, we explored tracking tumor mutations in cell-free DNA (cfDNA) across post-treatment blood draws and comparing them to pre-treatment plasma and tissue profiles.

Methods

We retrospectively evaluated 235 samples collected from 24 subjects with late stage SCLC treated with first-line chemotherapy or chemoradiation in a prospective observational study. Tumor tissue samples were analyzed with the AVENIO Tumor Tissue Surveillance Kit (For Research Use Only, not for use in diagnostic procedures), a 198-kb next-generation sequencing panel covering 197 cancer genes. Matched peripheral blood mononuclear cells (PBMC), pre-treatment plasma, and multiple plasma from post-treatment timepoints were analyzed with the same panel using the AVENIO ctDNA Surveillance Kit (For Research Use Only, not for use in diagnostic procedures). A median input amount of 29 ng cfDNA, 129 ng tumor tissue DNA, and 50 ng PBMC DNA were sequenced to median deduplicated depths of 4491, 1315, and 6512, respectively. Somatic single nucleotide variants (SNVs) in tissue and plasma were identified by removing PBMC-matched germline or clonal hematopoietic mutations.

Results

We detected a median of 4 SNVs in tissue samples and a median of 100% (range 66 - 100%) of tissue SNVs in matched pre-treatment plasma. 96% (23/24) of subjects had at least one shared SNV between tissue and plasma, most commonly a TP53 mutation. A median of 7 SNVs were detected in pre-treatment plasma, whereas across all available post-treatment plasma (range 2 - 20 time points per subject), a median of 4 SNVs were detected. 53% of these mutations were not present in pre-treatment plasma or tissue.

Conclusions

Somatic mutations found in pre-treatment plasma were concordant with matched tissue, consistent with the highly metastatic nature of SCLC. ctDNA sequencing can provide additional molecular insights; in particular, detecting emergent mutations in ctDNA during treatment could advance our knowledge of SCLC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Roche Sequencing Solutions, Inc.

Funding

Roche Sequencing Solutions, Inc.

Disclosure

S. Yaung: Full / Part-time employment: Roche. C. Woestmann: Full / Part-time employment: Roche. L. Xi: Full / Part-time employment: Roche. C. Ju: Full / Part-time employment: Roche. B. Hinzmann: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. M. Thomas: Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Roche. F. Lasitschka: Research grant / Funding (institution): Roche. M. Meister: Research grant / Funding (institution): Roche. M. Schneider: Research grant / Funding (institution): Roche. F.J.F. Herth: Honoraria (institution): Roche. T. Muley: Research grant / Funding (institution), Licensing / Royalties: Roche. B. Wehnl: Full / Part-time employment: Roche. J. Palma: Shareholder / Stockholder / Stock options, Full / Part-time employment: Roche. X.M. Ma: Shareholder / Stockholder / Stock options, Licensing / Royalties, Full / Part-time employment: Roche.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.